|
T9590 |
T-1095
|
|
SGLT
,
transporter
|
|
T-1095 is an inhibitor of renal glucose reabsorption and the expression of Na+-glucose cotransporters (SGLTs) and facilitative glucose transporter 2 (GLUT2). |
|
T2385 |
Ipragliflozin
|
ASP1941 |
SGLT
|
|
Ipragliflozin (ASP1941) is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2. |
|
T67849 |
O-Desethyl Dapagliflozin
|
Empagliflozin-4 |
SGLT
|
|
O-Desethyl Dapagliflozin (Empagliflozin-4) is a SGLT2 inhibitor, IC50=33nM. |
|
T5016 |
Tofogliflozin (hydrate)
|
Tofogliflozin hydrate,CSG-452 hydrate |
SGLT
,
Reactive Oxygen Species
,
ROS
|
|
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific inhibitor of SGLT2(IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2). |
|
T34286 |
Remogliflozin etabonate
|
GSK189075,GSK 189075,GSK-189075A,GSK189075A,GSK-189075,GSK 189075A |
SGLT
|
|
Remogliflozin etabonate (GSK189075A) is a prodrug of regaliflozin and an inhibitor SGLT2 with Ki values of 1.95, 2.14, 8.57, and 43.1μM for hSGLT2, rSGLT2, rSGLT1, and hSGLT1, respectively. |
|
T1782 |
Canagliflozin
|
JNJ 24831754ZAE,JNJ 28431754AAA,TA 7284,JNJ 28431754 |
SGLT
|
|
Canagliflozin (JNJ 28431754AAA), a sodium-glucose transporter 2( SGLT2) and P-Glycoprotein inhibitor, is used in type 2 diabetes. |
|
T4999 |
Ertugliflozin
|
MK-8835,PF-04971729 |
SGLT
|
|
PF-04971729 (Ertugliflozin (PF-04971729)) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2). |
|
T2389 |
Dapagliflozin
|
BMS-512148 |
SGLT
,
HIF
|
|
Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. |
|
T4460 |
Dapagliflozin ((2S)-1,2-propanediol, hydrate)
|
BMS-512148 (2S)-1,2-propanediol, hydrate,Dapagliflozin propanediol monohydrate |
SGLT
|
|
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). It is in development for the tre... |
|
T3547 |
Sotagliflozin
|
LX-4211,LP-802034 |
SGLT
|
|
Sotagliflozin (LP-802034) is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. |
|
T68174 |
Sergliflozin A
|
|
SGLT
|
|
Sergliflozin A is a selective SGLT2 inhibitor that induces diabetes in a dose-dependent manner. It reduces hyperglycemia. |
|
T7217 |
Bexagliflozin
|
THR-1442,EGT1442,EGT0001442 |
SGLT
|
|
Bexagliflozin (EGT1442) is a potent, selective sodium glucose co-transporter 2 (SGLT2) inhibitor with IC50 values of 5.6 μM and 2 nM for human SGLT1 and SGLT2, respectively |
|
T16083 |
Mizagliflozin
|
GSK-1614235 free base,KGA-3235 free base,DSP-3235 free base |
SGLT
|
|
Mizagliflozin (GSK-1614235 free base) is a sodium-glucose transporter inhibitor( Ki of 27 nM for human SGLT1). Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic drug that ca... |
|
T15656 |
KGA-2727
|
|
SGLT
|
|
KGA-2727 is a potent and selective SGLT1 inhibitor, with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA... |
|
T28757 |
Sergliflozin etabonate
|
GW-869682,GW-869682X,KGT-1251,GW869682X,GW869682,KGT1251 |
SGLT
|
|
Sergliflozin etabonate (KGT-1251) is an inhibitor of SGLT2 and can be used in studies about type 2 diabetes and obesity. |
|
T1782L |
Canagliflozin hemihydrate
|
JNJ28431754,TA 7284,TA7284,TA-7284,JNJ 28431754,JNJ-28431754 |
SGLT
|
|
Canagliflozin hemihydrate (TA 7284) is a drug of the gliflozin class or subtype 2 sodium-glucose transport inhibitors used for the treatment of type 2 diabetes. SGLT2 is responsible for at least 90% of renal glucose reab... |
|
T1766 |
Empagliflozin
|
BI 10773 |
SGLT
|
|
Empagliflozin (BI 10773) is an SGLT-2 inhibitor (IC50=3.1 nM) that is potent and selective, with more than 300-fold selectivity for SGLT-1/4/5/6. Empagliflozin is used for the treatment of type 2 diabetes. |
|
T15244 |
Ertugliflozin L-pyroglutamic acid
|
PF-04971729 L-pyroglutamic acid |
Others
,
SGLT
|
|
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM. Ertugliflozin L-pyroglutamic acid can be used for studies about the treatmen... |
|
T11667 |
Ipragliflozin (L-Proline)
|
Ipragliflozin L-Proline |
Others
|
|
|
|
T15505 |
HSK0935
|
HSK 0935,HSK-0935 |
SGLT
|
|
|
|
T38539 |
Luseogliflozin hydrate
|
TS 071 hydrate |
|
|
Luseogliflozin (TS 071) hydrate, a second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor, exhibits selective potency and oral activity, with an IC50 of 2.26 nM. This compound is utilized in research for the... |
|
T15797 |
LX2761
|
|
Others
|
|
LX2761 is a chemically stable and effective inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 (IC50s: 2.2 nM and 2.7nM for hSGLT1 and hSGLT2). However, it shows specific SGLT1 inhibition in the... |
|
T21399 |
Luseogliflozin
|
TS71,TS-071,TS 71,TS071,TS-71,TS 071 |
|
|
Luseogliflozin, a potent and competitive inhibitor of sodium-dependent glucose cotransporter 2 (SGLT2), competitively inhibits human SGLT2-mediated glucose uptake with a Ki value of 1.10 nM. |
|
T30534 |
BMS-639432
|
|
|
|
BMS-639432 is a potent sodium-glucose cotransporter type II (SGLT2) inhibitor. |
|
T13179 |
Tofogliflozin
|
CSG452 |
Others
|
|
Tofogliflozin is a highly specific inhibitor of sodium/glucose cotransporter 2 (SGLT2) (Kis: 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2. IC50s: 2.9/14.9/6.4 nM (human/rat/mouse SGLT2)). |
|
T15752 |
Licogliflozin
|
LIK066 |
SGLT
|
|
Licogliflozin (LIK066) is an inhibitor of sodium-glucose cotransporter (SGLT1 and SGLT2). |
|
T32058 |
Henagliflozin
|
SHR3824,SHR 3824,SHR-3824 |
|
|
Henagliflozin (SHR3824) is an effective, oral, and selective SGLT2 inhibitor that effectively inhibits human SGLT2 in vitro, but has very weak inhibitory effects on human SGLT1. |
|
T24708 |
Remogliflozin
|
GSK189074,Remogliflozin A,GSK-189074,GSK 189074 |
|
|
Remogliflozin is an effective sodium-glucose transporter 2 inhibitor (Kis = 12.4 and 26 nM for human and rat SGLT2, respectively). |
|
T10958 |
Dapagliflozin-d5
|
BMS-512148 D5 |
Others
|
|
Dapagliflozin D5 (BMS-512148 D5) is deuterated Dapagliflozin. Dapagliflozin is a competitive SGLT2 inhibitor. |
|
T39966 |
SGLT1/2-IN-2
|
SGLT1/2-IN-2 |
|
|
SGLT1/2-IN-2 is a chemical compound with robust dual inhibitory properties, exhibiting potent activities against SGLT1 (IC50 = 96 nM) and SGLT2 (IC50 = 1.3 nM). |
|
T70390 |
YM-543 choline
|
|
|
|
YM-543, also known as ASP-543, is a selective SGLT2 inhibitor. Sodium-glucose cotransporter 2 (SGLT2) is a specifically expressed transporter in the kidney that plays an important role in renal glucose reabsorption, and ... |
|
T62830 |
SGLT1/2-IN-1
|
|
|
|
SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor. |
|
T10669 |
Canagliflozin-d4
|
Canagliflozin D4 |
Others
|
|
Canagliflozin D4 is a deuterium-labeled Canagliflozin. Canagliflozin is an SGLT2 inhibitor. |
|
T34767 |
TA-1887
|
TA 1887,TA1887 |
|
|
TA-1887 is a new type of selective inhibitor of sglt2 for the treatment of type 2 diabetes. It has a significant hypoglycemic effect in KK (HF-KK) mice fed a high-fat diet. TA-1887 has good pharmacokinetic characteristic... |
|
T72143 |
Velagliflozin proline hydrate
|
|
|
|
Velagliflozin proline hydrate, the clinical form of Velagliflozin, is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor exhibiting antidiabetic activity. By decreasing renal glucose reabsorption and promoting glyc... |
|
T35619 |
Dapagliflozin-3-O-β-D-Glucuronide
|
|
|
|
Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport.[1] Dapagliflozin is metab... |
|
T12892 |
SGL5213
|
|
SGLT
|
|
SGL5213 is an oral active and low-absorbable inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1)(hSGLT1 and hSGLT2 with IC50 values of 29 nM and 20 nM , respectively),and has potential to treat type 2 diabetes. |
|
T12893 |
SGLT inhibitor-1
|
|
SGLT
|
|
SGLT inhibitor-1 is a potentsodium glucose co-transporter proteins (SGLTs) dual inhibitor(hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively). |
